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Still Searching for the North Star*Subha V. Raman, MD, MSEE, Yasmin Siddiqui, DOAnd the end of all our exploring
Will be to arrive where we started
And know the place for the ﬁrst time.
—T. S. Eliot (1)“I nﬂammation of heart muscle” would seemto be a simple enough deﬁnition (2), yetdiagnostic uncertainty in myocarditis per-
sists. Misdiagnosis in self-limited cases may have
no consequence; in those with fulminant disease,
however, irrevocable consequences could ensue.
Overdiagnosis is also problematic, reducing the spec-
iﬁcity needed for directed therapy.
Cardiac magnetic resonance (CMR) has funda-
mentally altered the evaluation of myocarditis in
centers with suitable expertise and adherence to
quality standards (3–5). In patients with chest pain
and troponin elevation not due to acute coronary
syndrome (ACS), for instance, CMR helps establish
both diagnosis and prognosis (6,7). Although it
precisely quantiﬁes cardiac dysfunction, CMR is
primarily sought out in myocarditis for its tissue
characterization capacities. Contemporary myocar-
dial mapping techniques (8) have reduced uncer-
tainty in interpreting a tissue’s relative signal
intensity, noting that systemic inﬂammation that also
affects the reference tissue may obfuscate the latter
approach.SEE PAGE 667In this issue of iJACC, Radunski et al. (9) present
CMR ﬁndings in an important population of patients:
those with new-onset heart failure or symptoms of
acute chest pain with troponin T or N-terminal pro–* Editorials published in JACC: Cardiovascular Imaging reﬂect the views
of the authors and do not necessarily represent the views of JACC:
Cardiovascular Imaging or the American College of Cardiology.
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protocol included: T1- and T2-weighted imaging;
T1 mapping before and 15-min post-contrast with
calculation of the myocardial extracellular volume
fraction (ECV); T2 mapping; and late gadolinium
enhancement (LGE) imaging. All patients enrolled
were deemed to have myocarditis; thus, diagnostic
accuracy against this entry diagnosis was compared
among CMR-based tissue characterization tech-
niques alone or in combination, including the
Lake-Louise criteria, in which 2 of 3 abnormalities
(increased T2 signal intensity, early gadolinium
enhancement, and LGE) constitute presence of
myocarditis (10). In these patients, the authors found
superior diagnostic accuracy using ECV with LGE over
other approaches.
New imaging techniques claiming to represent
speciﬁc pathologies must pass through 2 important
stages. The ﬁrst is technical validation. Magnetic
resonance-based tissue characterization affords an
aggregate advantage in spatial resolution, temporal
resolution, contrast-to-noise ratio, and signal-to-
noise ratio; nonetheless, validation must be done
for its new approaches (11,12), as would be required
of any modality’s advances. This helps recognize
and account for technical confounders before one
equates the measurement of a signal to an inherent
property of the signal’s source. The authors provide
no such validation for the signal intensity
correction algorithm; thus, we cannot know if the
recognized problems with signal intensity analysis of
T2-weighted images obtained using a surface coil
were eliminated. Did their navigator-gated, motion-
corrected, spin-echo T2 mapping account for the
effects of cardiac motion and stimulated echoes
(13)? Prior validation in phantoms and healthy
volunteers would have engendered more conﬁdence
than it did. Potentially neglected technical consider-
ations may have measurable consequences: T2 values
were 10- to 30-ms shorter than those previously re-
ported in inﬂamed myocardium (14–16). This may
explain this work’s distinctly negative conclusions
regarding T2’s utility as a myocarditis biomarker
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677versus results from prior studies; technique limita-
tions similarly compromise conclusions drawn
regarding the diagnostic performance of the Lake-
Louise criteria (14,17–19).
Appropriately designed patient studies comprise
the second essential stage in translating novel imaging
techniques into insights on human disease. The
authors assure us that blood biomarker elevations did
not indicate ACS-induced damage; coronary angiog-
raphy ﬁndings or absence of infarct scar by LGE
could have given further credence to this claim. One
to 7 weeks transpired between presentation and
CMR, raising uncertainty as to what was being char-
acterized in the myocardium. Myocarditis is a disease
of phases: the initial injury takes place over a few
days, subacute immune reactions span several
weeks, and then remodeling may occur over weeks
to years (20). Inﬂammation may be conﬁned to and
decline rapidly over the ﬁrst 2 phases, when consid-
erable overlap exists with noninﬂammatory processes
such as volume shifts and altered energetics. Decom-
pensated heart failure itself expands the myocardial
interstitial space (21), potentially increasing ECV even
without concomitant inﬂammation. Thus, myocardial
characterization in patients up to 2 months after pre-
sentation may speak less to CMR’s ability to diagnose
myocarditis and more to its demonstration of the
sequelae of varied inciting mechanisms, which may
have included myocarditis.
The clinician will ask, “How do I manage patients
differently with these ﬁndings?” In individuals
with severe heart failure and suspected myocarditis,
endomyocardial biopsy may still be helpful; endo-
myocardial biopsy ﬁndings of giant cell myocarditis,for example, may prompt immunosuppression that
reduces mortality if quickly instituted (20,22).
Myocarditis management may also involve immuno-
modulatory and antiviral therapies (23), albeit within
narrow-bandwidth guidelines derived from clinical
trials that had limited guidance from tissue charac-
terization (24). Importantly, our best imaging bio-
markers have yet to be compared to in vitro
parameters such as inﬂammatory cell counts and
polymerase chain reaction ﬁndings.
Consider the potential value of a multicenter trial
comparing standardized T1, T2, ECV, and LGE mea-
surements to histopathological guideposts, all in the
context of what is happening clinically (with the
freshly minted work of Francone et al. (25) as a
step in the right direction). Better yet, include chil-
dren and adolescents to generate the evidence
needed to update their guidelines (26). Such a trial
would shift the imaging deliverable from a binary
outcome (myocarditis present/absent) to a more
reﬁned characterization of a condition that falls along
a continuum and likely requires a parallel spectrum
of treatments. By studying the histopathological
maps of yore to advance CMR-based quantiﬁcation of
inﬂammation, injury, and remodeling over the entire
myocardium, we may yet ﬁnd the “North Star”
that leads to better outcomes for patients presenting
at various stages of inﬂammatory myocardial disease.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Subha V. Raman, The Ohio State University, Davis
Heart and Lung Research Institute, 473 West 12th
Avenue, Suite 200, Columbus, Ohio 43210. E-mail:
Raman.1@osu.edu.RE F E RENCE S1. Eliot TS. Little gidding. In: Four Quartets.
Boston, MA: Houghton Mifﬂin Harcourt, 2014:59.
2. Bonow RO, Mann DL, Zipes DP, Libby P.
Myocarditis. In: Braunwald’s Heart Disease: A
Textbook of Cardiovascular Medicine. Ninth edi-
tion. Philadelphia, PA: Elsevier Saunders, 2012:
1595–610.
3. Friedrich MG, Marcotte F. Cardiac magnetic
resonance assessment of myocarditis. Circ Car-
diovasc Imaging 2013;6:833–9.
4. Schulz-Menger J, Bluemke DA, Bremerich J,
et al. Standardized image interpretation and post
processing in CMR. J Cardiovasc Magn Reson 2013;
15:35.
5. Kramer CM, Barkhausen J, Flamm SD, Kim RJ,
Nagel E, Society for Cardiovascular Magnetic
Resonance Board of Trustees Task Force on Stan-
dardized Protocols. Standardized CMR protocols:
2013 update. J Cardiovasc Magn Reson 2013;15:91.6. Assomull RG, Lyne JC, Keenan N, et al. The role
of cardiovascular magnetic resonance in patients
presenting with chest pain, raised troponin, and
unobstructed coronary arteries. Eur Heart J 2007;
28:1242–9.
7. Schumm J, Greulich S, Wagner A, et al. Cardio-
vascular magnetic resonance risk stratiﬁcation in
patients with clinically suspected myocarditis.
J Cardiovasc Magn Reson 2014;16:14.
8. Salerno M, Kramer CM. Advances in parametric
mapping with CMR imaging. J Am Coll Cardiol Img
2013;6:806–22.
9. Radunski UK, Lund GK, Stehning C, et al. CMR in
patients with severe myocarditis: diagnostic value
of quantitative tissue markers including extracel-
lular volume imaging. J Am Coll Cardiol Img 2014;
7:667–75.
10. Friedrich MG, Sechtem U, Schulz-Menger J,
et al. Cardiovascular magnetic resonance inmyocarditis: a JACC white paper. J Am Coll Cardiol
2009;53:1475–87.
11. Giri S, Chung YC, Merchant A, et al. T2 quanti-
ﬁcation for improved detection of myocardial
edema. J Cardiovasc Magn Reson 2009;11:56.
12. Messroghli DR, Greiser A, Frohlich M, Dietz R,
Schulz-Menger J. Optimization and validation of
a fully-integrated pulse sequence for modiﬁed
look-locker inversion-recovery (MOLLI) T1 map-
ping of the heart. J Magn Reson Imaging 2007;
26:1081–6.
13. Kim D, Jensen JH, Wu EX, Sheth SS,
BrittenhamGM.Breathholdmultiecho fast spin-echo
pulse sequence for accurate R2 measurement in the
heart and liver. Magn Reson Med 2009;62:300–6.
14. Thavendiranathan P, Walls M, Giri S, et al.
Improved detection of myocardial involvement
in acute inﬂammatory cardiomyopathies using T2
mapping. Circ Cardiovasc Imaging 2012;5:102–10.
Raman and Siddiqui J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 7 , N O . 7 , 2 0 1 4
Editorial Comment J U L Y 2 0 1 4 : 6 7 6 – 8
67815. Park CH, Choi EY, Greiser A, Paek MY,
Hwang SH, Kim TH. Diagnosis of acute global
myocarditis using cardiac MRI with quantitative t1
and t2 mapping: case report and literature review.
Korean J Radiol 2013;14:727–32.
16. Usman AA, Taimen K, Wasielewski M, et al.
Cardiac magnetic resonance T2 mapping in the
monitoring and follow-up of acute cardiac trans-
plant rejection: a pilot study. Circ Cardiovasc
Imaging 2012;5:782–90.
17. Abdel-Aty H, Boye P, Zagrosek A, et al. Diag-
nostic performance of cardiovascular magnetic
resonance in patients with suspected acute
myocarditis: comparison of different approaches.
J Am Coll Cardiol 2005;45:1815–22.
18. Chu GC, Flewitt JA, Mikami Y, Vermes E,
Friedrich MG. Assessment of acute myocarditis by
cardiovascular MR: diagnostic performance ofshortened protocols. Int J Cardiovasc Imaging
2013;29:1077–83.
19. Zagrosek A, Abdel-Aty H, Boye P, et al. Cardiac
magnetic resonance monitors reversible and irre-
versible myocardial injury in myocarditis. J Am Coll
Cardiol Img 2009;2:131–8.
20. Kindermann I, Barth C,Mahfoud F, et al. Update
on myocarditis. J Am Coll Cardiol 2012;59:779–92.
21. Boyle A, Maurer MS, Sobotka PA. Myocellular
and interstitial edema and circulating volume
expansion as a cause of morbidity and mortality in
heart failure. J Card Fail 2007;13:133–6.
22. Cooper LT, Baughman KL, Feldman AM, et al.
The role of endomyocardial biopsy in the
management of cardiovascular disease. J Am Coll
Cardiol 2007;50:1914–31.
23. Caforio AL, Pankuweit S, Arbustini E, et al.
Current state of knowledge on aetiology,diagnosis, management, and therapy of myocar-
ditis. Eur Heart J 2013;34:2636–48, 2648a–d.
24. Maisch B, Pankuweit S. Standard and etiology-
directed evidence-based therapies in myocarditis:
state of the art and future perspectives. Heart Fail
Rev 2013;18:761–95.
25. Francone M, Chimenti C, Galea N, et al. CMR
sensitivity varies with clinical presentation and
extent of cell necrosis in biopsy-proven acute
myocarditis. J Am Coll Cardiol Img 2014;7:254–63.
26. Kantor PF, Lougheed J, Dancea A, et al. Pre-
sentation, diagnosis, and medical management of
heart failure in children. Can J Cardiol 2013;29:
1535–52.
KEY WORDS cardiac magnetic resonance,
extracellular volume, myocarditis, T1 mapping,
T2 mapping
